Sitagliptin compared to glimepiride on vascular risk factors among patients with type 2 diabetes mellitus

Effect of sitagliptin compared to glimepiride on vascular risk factors among patients with type 2 diabetes mellitus

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

SLCTR

Registry ID

SLCTR/2015/022

Enrollment

Unknown

Registered

2015-09-28

Start date

2015-09-28

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes Mellitus

Interventions

Patients will be selected from the Medical and Endocrinology clinics of the Teaching Hospital, Karapitiya. Following screening and recruitment based on eligibility criteria by the principal investigat

Eligibility

Inclusion criteria

Inclusion criteria: 1. Age > 20 years 2. On metformin 2g per day or the maximum tolerable dose for the patient. 3. Any one of the following indicators of poor glycaemic control • HbA1C > 8% in last clinic visit or • FBS > 150 mg/dl in each visit for the last three months or • RBS > 200 mg/dl in each visit for the last three months

Exclusion criteria

Exclusion criteria: 1. Pregnant women 2. Patients on oral hypoglycemic agents other than metformin 3. Patients with cardiovascular diseases like ischemic heart disease, heart failure, and arrhythmia. 4. Patients with cerebrovascular accidents 5. Patients with stage 4,5 renal disease 6. Patients with acute illnesses 7. Patients already on drugs to modify the vascular risk factors, • anti-platelets • anti anginals • lipid lowering drugs • folic acid • anti-inflammatory drugs • anticoagulants

Design outcomes

Primary

Measure	Time frame
1. Glycemic control (Fasting Blood Glucose, HbA1C) 2. Insulin resistance (Fasting Insulin and fasting blood glucose. Insulin resistance will be calculated by HOMA-IR method). 3. Serum fibrinogen level 4. Lipid profile 5. High sensitivity C reactive protein (Hs CRP) 6. Serum homocystein 7. Serum creatinine 8. eGFR 9. Serum alanine and aspartate transaminase 10. Serum amylase [At baseline and at the end of 3 months]	—

Measure

Time frame

1. Glycemic control (Fasting Blood Glucose, HbA1C) 2. Insulin resistance (Fasting Insulin and fasting blood glucose. Insulin resistance will be calculated by HOMA-IR method). 3. Serum fibrinogen level 4. Lipid profile 5. High sensitivity C reactive protein (Hs CRP) 6. Serum homocystein 7. Serum creatinine 8. eGFR 9. Serum alanine and aspartate transaminase 10. Serum amylase [At baseline and at the end of 3 months]

—

Secondary

Measure	Time frame
Blood pressure [Baseline and monthly for 3 months]	—

Countries

Sri Lanka

Contacts

Public ContactAruma Thantirige Isuru Madushika Amarasinghe

Lecturer (Probationary)

amarasingheisuru@yahoo.comTel: 0912246877

Outcome results

None listed

Source: SLCTR (via WHO ICTRP) · Data processed: Aug 9, 2026